A PHASE-II TRIAL OF DIAZIQUONE (AZQ) IN MIXED MESODERMAL SARCOMAS OF THE UTERUS - A GYNECOLOGIC ONCOLOGY GROUP-STUDY

被引：0
|
作者：
SLAYTON, RE
BLESSING, JA
CLARKEPEARSON, D
机构：
[1] RUSH PRESBYTERIAN ST LUKES MED CTR,DEPT MED,MED ONCOL SECT,CHICAGO,IL 60612
[2] ROSWELL PK CANC INST,GYNECOL ONCOL GRP,BUFFALO,NY
[3] DUKE UNIV,MED CTR,DEPT OBSTET & GYNECOL,DIV GYNECOL ONCOL,DURHAM,NC 27710
来源：
INVESTIGATIONAL NEW DRUGS | 1991年 / 9卷 / 01期
关键词：
DIAZIQUONE; MIXED MESODERMAL SARCOMA; UTERUS;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
AZQ was given intravenously to 23 patients with mixed mesodermal sarcoma of the uterus refractory to conventional treatment at a dose of 22.5-30 mg/m2 q three weeks. There was one partial response lasting seven weeks and one drug-related death. Based upon the activity observed in this trial, there does not appear to be a significant role for AZQ as a salvage agent for mixed mesodermal sarcomas of the uterus at the dose and schedule tested.
引用
收藏
页码：93 / 94
页数：2
相关论文
共 50 条
  • [21] PHASE-II TRIAL OF DIAZIQUONE (AZQ) IN ADVANCED MALIGNANT-MELANOMA
    HOST, H
    JOSS, R
    PINEDO, H
    BRUNTSCH, U
    CAVALLI, F
    RENARD, G
    VANGIABBEKE, M
    ROZENCWEIG, M
    EUROPEAN JOURNAL OF CANCER & CLINICAL ONCOLOGY, 1983, 19 (02): : 295 - 298
  • [22] PHASE-II TRIAL OF CISPLATIN AS 1ST-LINE CHEMOTHERAPY IN PATIENTS WITH ADVANCED OR RECURRENT UTERINE SARCOMAS - A GYNECOLOGIC ONCOLOGY GROUP-STUDY
    THIGPEN, JT
    BLESSING, JA
    BEECHAM, J
    HOMESLEY, H
    YORDAN, E
    JOURNAL OF CLINICAL ONCOLOGY, 1991, 9 (11) : 1962 - 1966
  • [23] PHASE-II STUDY OF DIAZIQUONE IN ADVANCED SOFT-TISSUE AND BONY SARCOMA - A SOUTHWEST ONCOLOGY GROUP-STUDY
    ZIDAR, BL
    BAKER, LH
    RIVKIN, SE
    BALCERZAK, SP
    STEPHENS, RL
    CANCER TREATMENT REPORTS, 1985, 69 (09): : 1035 - 1036
  • [24] PHASE-II STUDY OF IFOSFAMIDE AND MESNA IN NONSQUAMOUS CARCINOMA OF THE CERVIX - A GYNECOLOGIC ONCOLOGY GROUP-STUDY
    SUTTON, GP
    BLESSING, JA
    DISAIA, PJ
    MCGUIRE, WP
    GYNECOLOGIC ONCOLOGY, 1993, 49 (01) : 48 - 50
  • [25] PHASE-II TRIAL OF ACIVICIN IN PATIENTS WITH ADVANCED EPITHELIAL OVARIAN-CARCINOMA - A GYNECOLOGIC ONCOLOGY GROUP-STUDY
    MCGUIRE, WP
    BLESSING, JA
    DISAIA, PJ
    BUCHSBAUM, HJ
    INVESTIGATIONAL NEW DRUGS, 1986, 4 (01) : 49 - 52
  • [26] Phase II trial of hydroxyurea, dacarbazine (DTIC), and etoposide (VP-16) in mixed mesodermal tumors of the uterus: A gynecologic oncology group study
    Currie, JL
    Blessing, JA
    McGehee, R
    Soper, JT
    Berman, M
    GYNECOLOGIC ONCOLOGY, 1996, 61 (01) : 94 - 96
  • [27] A phase II trial of aminothiadiazole in patients with mixed mesodermal tumors of the uterine corpus: A gynecologic oncology group study
    Asbury, R
    Blessing, JA
    Moore, D
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 1996, 19 (04): : 400 - 402
  • [28] PHASE-II TRIAL OF MENOGARIL IN ADENOCARCINOMA OF THE PANCREAS - A SOUTHWEST ONCOLOGY GROUP-STUDY
    BROWN, TD
    GOODMAN, PJ
    FLEMING, TR
    BAKER, LH
    MACDONALD, JS
    INVESTIGATIONAL NEW DRUGS, 1991, 9 (01) : 77 - 78
  • [29] PHASE-II TRIAL OF ETOPOSIDE IN THE MANAGEMENT OF ADVANCED AND RECURRENT LEIOMYOSARCOMA OF THE UTERUS - A GYNECOLOGIC-ONCOLOGY-GROUP STUDY
    SLAYTON, RE
    BLESSING, JA
    ANGEL, C
    BERMAN, M
    CANCER TREATMENT REPORTS, 1987, 71 (12): : 1303 - 1304
  • [30] Phase II trial of paclitaxel in leiomyosarcoma of the uterus: A Gynecologic Oncology Group study
    Sutton, G
    Blessing, JA
    Ball, H
    GYNECOLOGIC ONCOLOGY, 1999, 74 (03) : 346 - 349
12345